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Background
Up to 75% of the patients with heart transplant present
signs of an infectious episode within the first year post-
heart transplant. Objectives: assessment of infections
prevalence, correlation between cytomegalovirus (CMV)
infection and post-transplant complications, occurrence
of acute rejection and allograft vessel disease.
Methods
37 patients who underwent orthotopic heart transplanta-
tion have been followed for a period of five years. Post-
transplantation screening has been performed over the
following etiological agents: CMV, hepatitis B virus,
hepatitis C virus, Epstein-Barr virus and Toxoplasma
gondii. Receptors with criteria for CMV IgG and Toxo-
plasma IgG antibodies have been accepted. Infectious
episodes at 1, 6 and 12 months and evolution depending
on CMV screening results, correlated with infection,
acute rejection and allograft vessel disease have been
pursued. Microbiological techniques, echocardiography,
chest X-ray and endomyocardial biopsy have been per-
formed for diagnosis.
Results
The mean age of patients was 38.5 years. Within the
range of 1 to 6 months, a number of 50 infectious epi-
sodes (IE) were identified, with an average rate of 1.35 IE
occurrences per patient. After 6 months 68 IE were iden-
tified, with an average rate of 1.83 IE occurrences per
patient. After 1 year, 22 IE were identified with an aver-
age rate of 0.59 IE occurrences per patient. Following the
correlation between CMV IgG antibodies after one year
and bacterial infections, 2 pulmonary infections, 4 cases
of upper respiratory tract infections, 3 cases of urinary
tract infections, and one sepsis case were noted. Con-
cerning the viral infections, out of the 26 patients with
CMV IgG positive antibodies 16 (61.5%) did not develop
infections, 6 patients were CMV IgM antibodies positive,
3 were noted with viral pneumonia, 2 varicella zoster
virus cases and one with herpes simplex virus infection
were also found.
The correlation between the presence or absence of
CMV IgG antibodies and rejection score has been fol-
lowed. 9 CMV IgG antibody positive patients (34.6%) had
the rejection score 1, 15 (57.7%) were found with rejec-
tion score 0. In CMV serology negative patients a 0 to 6
out of 11 rejection score (54.5%) was identified. The four
allograft vessel diseases recorded in the study group were
found in CMV IgG antibodies patients.
Conclusion
During the evolution a decrease in survival rate related
to CMV chronic infection has not been observed, but its
role in the development of allograft vessel disease has
been confirmed.
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